[1]明静,谢立科,秦睿.视网膜分支静脉阻塞继发黄斑水肿的治疗进展[J].眼科新进展,2020,40(9):879-884.[doi:10.13389/j.cnki.rao.2020.0200]
　MING Jing,XIE Like,QIN Rui.Recent advances in treatment of macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2020,40(9):879-884.[doi:10.13389/j.cnki.rao.2020.0200]
点击复制

视网膜分支静脉阻塞继发黄斑水肿的治疗进展/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
40卷
期数:
2020年9期
页码:
879-884
栏目:
文献综述
出版日期:
2020-09-05

文章信息/Info

Title:
Recent advances in treatment of macular edema secondary to branch retinal vein occlusion
作者:
明静; 谢立科; 秦睿
100040　北京市，中国中医科学院眼科医院白内障眼病2科
Author(s):
MING Jing; XIE Like; QIN Rui
Department of Cataract No.2,Eye Hospital,China Academy of Chinese Medical Sciences,Beijing 100040,China
关键词:
视网膜分支静脉阻塞; 黄斑水肿; 治疗
Keywords:
branch retinal vein occlusion; macular edema; treatment
分类号:
R774.1
DOI:
10.13389/j.cnki.rao.2020.0200
文献标志码:
A
摘要:
黄斑水肿（macular edema， ME）是视网膜分支静脉阻塞（branch retinal vein occlusion，BRVO）的常见并发症，也是导致视力下降的主要原因。目前，BRVO继发ME的治疗主要包括黄斑格栅样激光光凝和玻璃体内注射激素或抗血管内皮生长因子药物。激素类药物主要包括曲安奈德和地塞米松玻璃体植入剂，抗血管内皮生长因子药物包括雷珠单抗、贝伐单抗、阿柏西普、康柏西普。玻璃体切割术是BRVO继发ME一种有前景的治疗方法。
Abstract:
Macular edema is a common complication of branch retinal vein occlusion damaging visual function. At present, the treatment of macular edema secondary to branch retinal vein occlusion mainly includes macular grid-pattern laser photocoagulation and intravitreal injection of glucocorticoids or anti-vascular endothelial growth factor drugs. Glucocorticoids drugs mainly include triamcinolone acetonide and dexamethasone intravitreal implants. Anti-vascular endothelial growth factor drugs include ranibizumab, bevacizumab, aflibercept, and conbercept. In addition, vitrectomy is a promising treatment.

参考文献/References:

［1］KLEIN R,MOSS S E,MEUER S M,KLEIN B E.The 15-year cumulative incidence of retinal vein occlusion:the Beaver Dam Eye Study［J］.Arch Ophthalmol,2008,126(4):513-518.
［2］　LAM F C,CHIA S N,LEE R M H.Macular grid laser photocoagulation for branch retinal vein occlusion［J］.Cochrane Database Syst Rev,2015,(5):1-65.
［3］　CAMPOCHIARO P A,HEIER J S,FEINER L,GRAY S,SAROJ N,RUNDLE A C,et al.Ranibizumab for macular edema following branch retinal vein occlusion:six-month primary end point results of a phase Ⅲ study［J］.Ophthalmology,2010,117(6):1102-1112.
［4］　GLANVILLE J,PATTERSON J,MCCOOL R,FERREIRA A,GAIRY K,PEARCE I.Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion:a systematic review［J］.BMC Ophthalmol,2014,14:7.
［5］　PATZ A.Argon laser photocoagulation for macular edema in branch vein occlusion［J］.Am J Ophthalmol,1984,98(3):374-375.
［6］　HALLER J A,BANDELLO F,BELFORT R J R,BLUMENKRANZ M S,GILLIES M,HEIER J,et al.Randomized,sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion［J］.Ophthalmology,2010,117(6):1134-1146.
［7］　NARAYANAN R,PANCHAL B,DAS T,CHHABLANI J,JALALI S,ALI M H.A randomised,double-masked,controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion:MARVEL Report No.1［J］.Br J Ophthalmol,2015,99(7):954-959.
［8］　CAMPOCHIARO P A,CLARK W L,BOYER D S,HEIER J S,BROWN D M,VITTI R,et al.Intravitreal aflibercept for macular edema following branch retinal vein occlusion:the 24-week results of the VIBRANT study［J］.Ophthalmology,2015,122(3):538-544.
［9］　ARNARSSON A,STEFANSSON E.Laser treatment and the mechanism of edema reduction in branch retinal vein occlusion［J］.Invest Ophthalmol Vis Sci,2000,41(3):877-879.
［10］　TADAYONI R,WALDSTEIN S M,BOSCIA F,GERDING H,GEKKIEVA M,BARNES E,et al.Sustained benefits of ranibizumab with or without Laser in branch retinal vein occlusion:24-month results of the BRIGHTER study［J］.Ophthalmology,2017,124(12):1778-1787.
［11］　HATTENBACH L O,FELTGEN N,BERTELMANN T,SCHMITZ-VALCKENBERG S,BERK H,ETER N,et al.Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B)［J］.Acta Ophthalmol,2018,96(1):e10-e18.
［12］　MOLNAR I,POITRY S,TSACOPOULOS M,GILODI N,LEUENBERGER P M.Effect of laser photocoagulation on oxygenation of the retina in miniature pigs［J］.Invest Ophthalmol Vis Sci,1985,26(10):1410-1414.
［13］　GOTTFREDSDOTTIR M S,STEFANSSON E,JONASSON F,GISLASON I.Retinal vasoconstriction after laser treatment for diabetic macular edema［J］.Am J Ophthalmol,1993,115(1):64-67.
［14］　SCOTT I U,IP M S,VANVELDHUISEN P C,ODEN N L,BLODI B A,FISHER M,et al.A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion:the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6［J］.Arch Ophthalmol,2009,127(9):1115-1128.
［15］　CAO W,CUI H,BISKUP E.Combination of grid laser photocoagulation and a single intravitreal ranibizumab as an efficient and cost-effective treatment option for macular edema secondary to branch retinal vein occlusion［J］.Rejuvenation Res,2019,22(4):335-341.
［16］　JONAS J B,JONAS R A,NEUMAIER M,FINDEISEN P.Cytokine concentration in aqueous humor of eyes with diabetic macular edema［J］.Retina,2012,32(10):2150-2157.
［17］　DEMIR M,OBA E,GUVEN D,ACAR Z,CINAR S.Results of intravitreal triamcinolone acetonide in patients with macular edema secondary to branch retinal vein occlusion［J］.Int J Clin Pharm,2014,36(2):438-442.
［18］　KOLA M,HACIOGLU D,TURK A,ERDOL H.The effectiveness and reliability of posterior sub-Tenon triamcinolone acetonide injection in branch retinal vein occlusion-related macular edema［J］.Cutan Ocul Toxicol,2016,35(3):185-189.
［19］　HALLER J A,BANDELLO F,BELFORT R,BLUMENKRANZ M S,GILLIES M,HEIER J,et al.Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results［J］.Ophthalmology,2011,118(12):2453-2460.
［20］　YOON Y H,KIM J W,LEE J Y,KIM I T,KANG S W,YU H G,et al.Dexamethasone intravitreal implant for early treatment and retreatment of macular edema related to branch retinal vein occlusion:the multicenter COBALT study［J］.Ophthalmologica,2018,240(2):81-89.
［21］　SIMSEK M,CITIRIK M,OZATES S,OZKOYUNCU D.The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario［J］.Indian J Ophthalmol,2018,66(6):831-836.
［22］　LAINE I,LINDHOLM J M,YLINEN P,TUUMINEN R.Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naive retinal vein occlusion related macular edema［J］.Clin Ophthalmol,2017,11:2107-2112.
［23］　GAO L,ZHOU L,TIAN C,LI N,SHAO W,PENG X,et al.Intravitreal dexamethasone implants versus intravitreal anti-VEGF treatment in treating patients with retinal vein occlusion:a meta-analysis［J］.BMC Ophthalmol,2019,19(1):8.
［24］　BANDELLO F,AUGUSTIN A,TUFAIL A,LEABACK R.A 12-month,multicenter,parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion［J］.Eur J Ophthalmol,2018,28(6):697-705.
［25］　MOON S Y,CHO K H,WOO S J,PARK S P,KIM Y K.Bevacizumab versus dexamethasone implant followed by Bevacizumab for the treatment of macula edema associated with branch retinal vein occlusion［J］.Korean J Ophthalmol,2018,32(1):29-37.
［26］　BAHADORANI S,KRAMBEER C,WANNAMAKER K,TIE W,JANSEN M,ESPITIA J,et al.The effects of repeated Ozurdex injections on ocular hypertension［J］.Clin Ophthalmol,2018,12:639-642.
［27］　MISHRA S K,GUPTA A,PATYAL S,KUMAR S,RAJI K,SINGH A,et al.Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion:quantifying efficacy and safety［J］.Int J Retina Vitreous,2018,4:13.
［28］　GLER H A,RNEK N,RNEK K,BYKTORTOP GKINAR N,O G UREL T,YUMU AK M E,et al.Effect of dexamethasone intravitreal implant (Ozurdex?) on corneal endothelium in retinal vein occlusion patients:Corneal endothelium after dexamethasone implant injection［J］.BMC Ophthalmol,2018,18(1):235.
［29］　ILHAN N,COSKUN M,ILHAN O,AYHAN TUZCU E,DAGLIOGLU M C,ELBEYLI A,et al.Effect of intravitreal injection of dexamethasone implant on corneal endothelium in macular edema due to retinal vein occlusion［J］.Cutan Ocul Toxicol,2015,34(4):294-297.
［30］　RAHIMY E,KHURANA R N.Anterior segment migration of dexamethasone implant:risk factors,complications,and management［J］.Curr Opin Ophthalmol,2017,28(3):246-251.
［31］　OZAKI H,HAYASHI H,VINORES S A,MOROMIZATO Y,CAMPOCHIARO P A,OSHIMA K.Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates［J］.Exp Eye Res,1997,64(4):505-517.
［32］　AIELLO L P,AVERY R L,ARRIGG P G,KEYT B A,JAMPEL H D,SHAH S T,et al.Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders［J］.N Engl J Med,1994,331(22):1480-1487.
［33］　CAMPOCHIARO P A,HAFIZ G,SHAH S M,NGUYEN Q D,YING H,DO D V,et al.Ranibizumab for macular edema due to retinal vein occlusions:implication of VEGF as a critical stimulator［J］.Mol Ther,2008,16(4):791-799.
［34］　NOMA H,FUNATSU H,YAMASAKI M,TSUKAMOTO H,MIMURA T,SONE T,et al.Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6［J］.Am J Ophthalmol,2005,140(2):256-261.
［35］　EHLERS J P,KIM S J,YEH S,THORNE J E,MRUTHYUNJAYA P,SCHOENBERGER S D,et al.Therapies for macular edema associated with branch retinal vein occlusion:a report by the american academy of ophthalmology［J］.Ophthalmology,2017,124(9):1412-1423.
［36］　JAIN P,SHETH J,ANANTHARAMAN G,GOPALAKRISHNAN M.Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario［J］.Indian J Ophthalmol,2017,65(7):596-602.
［37］　RISHI P,RAKA N,RISHI E.Analysis of potential ischemic effect of intravitreal bevacizumab on unaffected retina in treatment-naive macular edema due to branch retinal vein occlusion:a prospective,interventional case-series［J］.PLoS ONE,2016,11(9):e0162533.
［38］　CEHOFSKI L J,KRUSE A,ALSING A N,NIELSEN J E,PEDERSEN S,KIRKEBY S,et al.Intravitreal bevacizumab upregulates transthyretin in experimental branch retinal vein occlusion［J］.Mol Vis,2018,24:759-766.
［39］　KIDA T,FLAMMER J,OKU H,MORISHITA S,FUKUMOTO M,SUZUKI H,et al.Suppressed endothelin-1 by anti-VEGF therapy is important for patients with BRVO-related macular edema to improve their vision［J］.Epma J,2016,7(1):18.
［40］　NOMA H,MIMURA T,YASUDA K,SHIMURA M.Cytokine kinetics after monthly intravitreal Bevacizumab for retinal vein occlusion associated with macular oedema［J］.Ophthalmic Res,2016,56(4):207-214.
［41］　AZHAR M N,MUZAFFAR W,ARAIN M A,FAROOQ O.Intravitreal Bevacizumab (IVB) for macular edema secondary to branch retinal vein occlusion (BRVO)［J］.J Coll Physicians Surg Pak,2018,28(10):758-761.
［42］　CALLIZO J,ATILI A,STRIEBE N A,BEMME S,FELTGEN N,HOERAUF H,et al.Bevacizumab versus bevacizumab and macular grid photocoagulation for macular edema in eyes with non-ischemic branch retinal vein occlusion:results from a prospective randomized study［J］.Graefes Arch Clin Exp Ophthalmol,2019,257(5):913-920.
［43］　KARTASASMITA A S,TAKARAI S,SWITANIA A,ENUS S.Efficacy of single bevacizumab injection as adjuvant therapy to laser photocoagulation in macular edema secondary to branch retinal vein occlusion［J］.Clin Ophthalmol,2016,10:2135-2140.
［44］　LEE K H,KANG E C,KOH H J.Dexamethasone intravitreal implant rescue treatment for bevacizumab refractory macular edema secondary to branch retinal vein occlusion［J］.Korean J Ophthalmol,2017,31(2):108-114.
［45］　MOON J,KIM M,SAGONG M.Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion［J］.Eye,2016,30(8):1084-1090.
［46］　FUKAMI M,IWASE T,YAMAMOTO K,KANEKO H,YASUDA S,TERASAKI H.Changes in retinal microcirculation after intravitreal Ranibizumab injection in eyes with macular edema secondary to branch retinal vein occlusion［J］.Invest Ophthalmol Vis Sci,2017,58(2):1246-1255.
［47］　KAWAMURA M,HIRANO Y,YOSHIDA M,MIZUTANI T,SUGITANI K,YASUKAWA T,et al.Six-month results of intravitreal ranibizumab for macular edema after branch retinal vein occlusion in a single-center prospective study:visual outcomes and microaneurysm formation［J］.Clin Ophthalmol,2018,12:1487-1494.
［48］　MIWA Y,MURAOKA Y,OSAKA R,OOTO S,MURAKAMI T,SUZUMA K,et al.Ranibizumab for macular edema after branch retinal vein occlusion:one initial injection versus three monthly injections［J］.Retina,2017,37(4):702-709.
［49］　KUMLUANG S,INGSRISAWANG L,SANGROONGRUANGSRI S,CHAIKLEDKAEW U,RATANAPAKORN T,RUAMVIBOONSUK P,et al.A real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in Thailand［J］.BMC Ophthalmol,2019,19(1):82.
［50］　FELTGEN N,HATTENBACH L O,BERTELMANN T,CALLIZO J,REHAK M,WOLF A,et al.Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion:1-year results of the COMRADE extension study［J］.Acta Ophthalmol,2018,96(8):e933-e941.
［51］　OZKAYA A,TARAKCIOGLU H N,TANIR I.Ranibizumab versus Dexamethasone implant in macular edema secondary to branch retinal vein occlusion:Two-year outcomes［J］.Optom Vis Sci,2018,95(12):1149-1154.
［52］　KHAN M,WAI K M,SILVA F Q,SRIVASTAVA S,EHLERS J P,RACHITSKAYA A,et al.Comparison of Ranibizumab and Bevacizumab for macular edema secondary to retinal vein occlusions in routine clinical practice［J］.Ophthalmic Surg Lasers Imaging Retina,2017,48(6):465-472.
［53］　SON B K,KWAK H W,KIM E S,YU S Y.Comparison of Ranibizumab and Bevacizumab for macular edema associated with branch retinal vein occlusion［J］.Korean J Ophthalmol,2017,31(3):209-216.
［54］　VAZ-PEREIRA S,MARQUES I P,MATIAS J,MIRA F,RIBEIRO L,FLORES R.Real-world outcomes of anti-VEGF treatment for retinal vein occlusion in portugal［J］.Eur J Ophthalmol,2017,27(6):756-761.
［55］　LI F,SUN M,GUO J,MA A,ZHAO B.Comparison of conbercept with ranibizumab for the treatment of macular edema secondary to branch retinal vein occlusion［J］.Curr Eye Res,2017,42(8):1174-1178.
［56］　JUMPER J M,DUGEL P U,CHEN S,BLINDER K J,WALT J G.Anti-VEGF treatment of macular edema associated with retinal vein occlusion:patterns of use and effectiveness in clinical practice (ECHO study report 2)［J］.Clin Ophthalmol,2018,12:621-629.
［57］　TERASHIMA H,HASEBE H,OKAMOTO F,MATSUOKA N,SATO Y,FUKUCHI T.Combination therapy of intravitreal ranibizumab and subthreshold micropulse photocoagulation for macular edema secondary to branch retinal vein occlusion:6-month result［J］.Retina,2019,39(7):1377-1384.
［58］　BUYRU OZKURT Y,AKKAYA S,AKSOY S,SIMSEK M H.Comparison of ranibizumab and subthreshold micropulse laser in treatment of macular edema secondary to branch retinal vein occlusion［J］.Eur J Ophthalmol,2018,28(6):690-696.
［59］　ANDRADE G C,DIAS J R O,MAIA A,FARAH M E,MITNE S,RODRIGUES E B.Intravitreal injections of ziv-aflibercept for the treatment of a patient with macular edema secondary to branch retinal vein occlusion［J］.Retin Cases Brief Rep,2018,12(2):93-96.
［60］　WANG J K,HUANG T L,SU P Y,CHANG P Y,TSENG Y Y.Intravitreal aflibercept for macular edema secondary to branch retinal vein occlusion in Chinese patients［J］.Eye Sci,2015,30(2):63-66,69.
［61］　CLARK W L,BOYER D S,HEIER J S,BROWN D M,HALLER J A,VITTI R,et al.Intravitreal Aflibercept for macular edema following branch retinal vein occlusion:52-week results of the VIBRANT study［J］.Ophthalmology,2016,123(2):330-336.
［62］　OZKAYA A,TULU B,GARIP R.Aflibercept in macular edema secondary to retinal vein occlusion:A real life study［J］.Saudi J Ophthalmol,2017,31(4):211-215.
［63］　KITCHENS J W,DO D V,BOYER D S,THOMPSON D,GIBSON A,SAROJ N,et al.Comprehensive review of ocular and systemic safety events with intravitreal Aflibercept injection in randomized controlled trials［J］.Ophthalmology,2016,123(7):1511-1520.
［64］　KONIDARIS V E,TSAOUSIS K T,ANZIDEI R,DE LA MATA G,BRENT A J.Real-world results of switching treatment from ranibizumab to aflibercept in macular oedema secondary to branch retinal vein occlusion［J］.Ophthalmol Ther,2018,7(2):387-395.
［65］　WIRTH M A,BECKER M D,GRAF N,MICHELS S.Aflibercept in branch retinal vein occlusion as second line therapy:clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab-a pilot study［J］.Int J Retina Vitreous,2016,2:1-5.
［66］　TAGAMI M,SAI R,FUKUDA M,AZUMI A.Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion［J］.Clin Ophthalmol,2017,11:403-408.
［67］　WANG J K,SU P Y,HSU Y R,CHEN Y J,CHEN F T,TSENG Y Y.Comparison of the efficacy of intravitreal aflibercept and bevacizumab for macular edema secondary to branch retinal vein occlusion［J］.J Ophthalmol,2016,2016:1-5.
［68］　SUN Z,ZHOU H,LIN B,JIAO X,LUO Y,ZHANG F,et al.Efficacy and safety of intravitreal conbercept injections in macular edema secondary to retinal vein occlusion［J］.Retina,2017,37(9):1723-1730.
［69］　SHIRAKATA Y,FUKUDA K,FUJITA T,NAKANO Y,NOMOTO H,YAMAJI H,et al.Pars plana vitrectomy combined with internal limiting membrane peeling for recurrent macular edema due to branch retinal vein occlusion after antivascular endothelial growth factor treatments［J］.Clin Ophthalmol,2016,10:277-283.
［70］　NISHIDA A,KOJIMA H,KAMEDA T,MANDAI M,KURIMOTO Y.Five-year outcomes of pars plana vitrectomy for macular edema associated with branch retinal vein occlusion［J］.Clin Ophthalmol,2017,11:369-375.

相似文献/References:

[1]李国兴 韩丽英.曲安奈德玻璃体腔注射治疗黄斑水肿[J].眼科新进展,2008,28(9):000.
[2]周正申 孙静芬.白内障超声乳化术后黄斑区光学相干断层扫描观察[J].眼科新进展,2013,33(2):000.
[3]刘广峰 蔺洁 范颖 顾铮 高新晓 朱岩 孟忻 王华 贾宇颂 付秀稳 汪军.非增生型糖尿病视网膜病变黄斑水肿患者黄斑区谱域光学相干断层扫描中高反射信号的特征分析[J].眼科新进展,2013,33(4):000.
[4]鲁丹 王康 王艳玲 林鹏耀 李茜 李明铭.后Tenon囊下注射曲安奈德辅助全视网膜光凝治疗糖尿病视网膜病变[J].眼科新进展,2013,33(5):000.
[5]陆秉文 吴星伟.视网膜静脉阻塞黄斑水肿患者玻璃体内注射ranibi-zumab后视野变化[J].眼科新进展,2013,33(12):000.
[6]徐斌 戴奕娟 梁丽 杨露. 传统格栅样激光与577nm黄色微脉冲激光光凝治疗黄斑水肿疗效对比[J].眼科新进展,2014,34(2):181.
[7]陈素芳 曾莉 邵毅. 非诺贝特在糖尿病视网膜病变中的应用进展[J].眼科新进展,2014,34(3):283.
[8]肖昂,周琼.Aflibercept治疗湿性AMD和黄斑水肿的相关研究现状[J].眼科新进展,2014,34(6):598.[doi:10.13389/j.cnki.rao.2014.0165]
[9]魏光杰,何佃菊.532nm绿激光格栅样光凝联合球内注药治疗糖尿病视网膜病变黄斑水肿[J].眼科新进展,2014,34(8):779.[doi:10.13389/j.cnki.rao.2014.0215]
　WEI Guang-Jie,HE Dian-Ju.532 run green grid laser photocoagulation combined with intravitreal Avastin injection for diabetic retinopathy macular edema[J].Recent Advances in Ophthalmology,2014,34(9):779.[doi:10.13389/j.cnki.rao.2014.0215]
[10]金昱,石安娜,刘淼. 玻璃体内注射雷珠单抗（Ranibizumab）治疗视网膜静脉阻塞继发黄斑水肿[J].眼科新进展,2014,34(9):855.[doi:10.13389/j.cnki.rao.2014.0236]
[11]张祺 冯劼 李培凤 金翼.Lucentis联合氪黄激光治疗视网膜分支静脉阻塞黄斑水肿的疗效观察[J].眼科新进展,2013,33(12):000.
[12]曹婷婷,陈桂芬,范玉香,等.视网膜分支静脉阻塞合并黄斑水肿不同治疗方法的疗效观察[J].眼科新进展,2014,34(8):772.[doi:10.13389/j.cnki.rao.2014.0213]
　CAO Ting-Ting,CHEN Gui-Fen,FAN Yu-Xiang,et al.Clinical observation in different treatment methods of branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2014,34(9):772.[doi:10.13389/j.cnki.rao.2014.0213]
[13]傅维娜,陈梅珠,王云鹏. Lucentis联合视网膜光凝治疗视网膜分支静脉阻塞继发黄斑水肿[J].眼科新进展,2015,35(3):270.[doi:10.13389/j.cnki.rao.2015.0072]
　FU Wei-Na,CHEN Mei-Zhu,WANG Yun-Peng. Intravitreal injection with lucentis combined with local retinal photocoagulation for macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2015,35(9):270.[doi:10.13389/j.cnki.rao.2015.0072]
[14]李仕永,高瑞莹,陈晖.雷珠单抗联合氩激光视网膜光凝治疗不同时期的视网膜分支静脉阻塞所致黄斑水肿的疗效[J].眼科新进展,2016,36(12):1161.[doi:10.13389/j.cnki.rao.2016.0309]
　LI Shi-Yong,GAO Rui-Ying,CHEN Hui.Effects of ranibizumab ( Lucentis) intravitreal injection combined with retinal argon laser photocoagulation on macular edema secondary to different period of branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(9):1161.[doi:10.13389/j.cnki.rao.2016.0309]
[15]刘广峰,洪婷婷,苗森,等.玻璃体内注射康柏西普与黄斑区光凝治疗视网膜分支静脉阻塞继发非缺血性黄斑水肿的临床对照研究[J].眼科新进展,2017,37(7):658.[doi:10.13389/j.cnki.rao.2017.0167]
　LIU Guang-Feng,HONG Ting-Ting,MIAO Sen,et al.Comparison of intravitreal injection of conbercept and macular photocoagulation for non-ischemic macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2017,37(9):658.[doi:10.13389/j.cnki.rao.2017.0167]
[16]石蕊,肖云芳,王峰,等.糖尿病合并视网膜分支静脉阻塞患者继发黄斑水肿后视力损伤程度及危险因素[J].眼科新进展,2017,37(12):1139.[doi:10.13389/j.cnki.rao.2017.0287]
　SHI Rui,XIAO Yun-Fang,WANG Feng,et al.Vision impairment following macular edema secondary to diabetes combined with branch retinal vein occlusion and its potential risk factors[J].Recent Advances in Ophthalmology,2017,37(9):1139.[doi:10.13389/j.cnki.rao.2017.0287]
[17]江慧娟,庞东渤.视网膜光凝联合玻璃体内注射雷珠单抗治疗缺血型视网膜分支静脉阻塞（BRVO）致黄斑水肿的疗效[J].眼科新进展,2018,38(4):348.[doi:10.13389/j.cnki.rao.2018.0081]
　JIANG Hui-Juan,PANG Dong-Bo.Efficacy of intravitreal ranibizumab combined with laser photocoagulation for the treatment of macular edema induced by ischemic branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2018,38(9):348.[doi:10.13389/j.cnki.rao.2018.0081]
[18]赵芃芃,秦梅.视网膜分支静脉阻塞治疗研究现状[J].眼科新进展,2018,38(5):485.[doi:10.13389/j.cnki.rao.2018.0114]
　ZHAO Peng-Peng,QIN Mei.Treatment research status of branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2018,38(9):485.[doi:10.13389/j.cnki.rao.2018.0114]
[19]林国乔,郑德志,陈伟奇.康柏西普治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿的临床研究[J].眼科新进展,2018,38(11):1055.[doi:10.13389/j.cnki.rao.2018.0248]
　LIN Guo-Qiao,ZHENG De-Zhi,CHEN Wei-Qi.Clinical outcomes of intravitreal Conbercept injection for macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2018,38(9):1055.[doi:10.13389/j.cnki.rao.2018.0248]
[20]杨大勇,李琳.雷珠单抗联合激光光凝术治疗视网膜分支静脉阻塞（BRVO）继发黄斑水肿疗效观察[J].眼科新进展,2019,39(4):369.[doi:10.13389/j.cnki.rao.2019.0084]
　YANG Da-Yong,LI Lin.Ranibizumab combined with laser photocoagulation in the treatment of patients with macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2019,39(9):369.[doi:10.13389/j.cnki.rao.2019.0084]

备注/Memo

备注/Memo:
北京市中医药科技发展资金项目（编号：JJ2018-95）
更新日期/Last Update: 2020-09-05